Praxis Precision Medicines Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
PRAX$332.97+19.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Collaboration revenue | $2,447 | $— |
| Operating expenses: | ||
| Research and development | 86,766 | 155,040 |
| General and administrative | 42,054 | 59,946 |
| Total operating expenses | 128,820 | 214,986 |
| Loss from operations | (126,373) | (214,986) |
| Other income: | ||
| Other income, net | 3,096 | 957 |
| Total other income | 3,096 | 957 |
| Net loss | $(123,277) | $(214,029) |
| Net loss per share attributable to common stockholders, basic and diluted1 | $(18.69) | $(69.65) |
| Weighted average common shares outstanding, basic and diluted1 | 6,594,316 | 3,073,100 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.